Scholar Rock Holding Corporation received FDA approval for ISEMBYLD, a new treatment for spinal muscular atrophy (SMA) targeting muscle function. This approval marks a significant advancement as the drug is the first muscle-targeted therapy for SMA, usable alongside existing treatments for both children and adults. Following this milestone, Citigroup maintained a "Buy" rating on Scholar Rock and raised its price target from $60 to $74, reflecting strong confidence in the company's growth prospects. Scholar Rock's stock is actively traded with a market cap of about $6.64 billion, indicating solid investor interest.
Morgan Stanley analyst Joe Laetsch raised Valero Energy's price target to $411, signaling a potential 3.18% upside from its current price. Institutional investors like Virginia Retirement Systems and Gamco Investors are initiating new positions, whil...
Hain Celestial reported a Q4 2026 loss per share of $0.05, missing analyst estimates of $0.03 loss, with revenues down to $263.07 million from $363.35 million a year ago. The company is selling its international business for $323 million to focus on ...
Roblox, an online gaming platform valued at $32.5 billion, saw its stock rise to $45.50 following major platform upgrades announced at its Developers Conference, including AI-assisted creation tools. Analyst firm Wedbush raised its price target from ...
SEALSQ Corp reported a 131% increase in revenue to $11.2 million for H1 2026, driven by strong demand for its secure semiconductor products and services. Despite this growth, the company posted a net loss of $27.8 million due to higher spending on re...
Evolution Petroleum Corporation will release its Q4 2026 earnings on September 15, with revenue expected to increase to $23.24 million from last year. However, earnings per share are projected to decline to $0.01 from $0.03, reflecting mixed financia...
